US biopharma manufacturing investment continues to gain momentum: reports
As 2026 comes to an end, two reports released this month point to increasing momentum in the life science market in the United States — particularly in biomanufacturing, where growth in domestic operations is driving employment in the sector to a 35-year high.
Commercial real estate firm Newmark’s 3Q26 U.S. Life Science Market Conditions & Trends report describes biomanufacturing as “one of the most significant green shoots” for the industry as hundreds of billions of dollars of capital have been committed to the onshoring of biopharmaceutical production in recent quarters.
A Q4 2026 Market Conditions report from general contractor DPR Construction credits a combination of policy and regulatory changes that are reshaping the life science industry’s commercial and manufacturing landscape, including Most-Favored-Nation (MFN) drug pricing, Medicare drug price negotiations under the Inflation Reduction Act, BIOSECURE Act restrictions, and efforts to bring biopharma manufacturing back to the U.S.
“Federal policy is guiding the life sciences industry toward domestic manufacturing resilience, supply chain security and advanced manufacturing productivity,” concludes DPR Construction, which notes that 26 large and mid-sized pharmaceutical manufacturers had entered into MFN pricing agreements with the Trump administration as of September 2026.
“Under the Administration’s Section 232 framework, manufacturers that paired MFN pricing commitments and onshoring agreements with the Department of Health and Human Services qualify for a 0% tariff rate through January 20, 2029,” the report states. “Together, these policies have accelerated domestic investment, with the same 26 MFN manufacturers committing approximately $170 billion toward U.S. manufacturing and research and development to bolster the U.S. pharmaceutical supply chain.”
Based on recent announcements, Big Pharma companies have collectively pledged upwards of approximately $500 billion in capital expenditures in U.S. manufacturing and R&D infrastructure, according to Newmark, which noted that biopharma manufacturing production is accelerating as investment expands.
“The industrial production of pharmaceuticals and medicine, which measures the real output of U.S.-based establishments, continued its upward trajectory through the third quarter of 2026,” the report found. “Early gains in 2025 were attributable to pharmaceutical companies front-loading production to mitigate tariff risks. Big Pharma is now looking to grow domestic operations.”
Thermo Fisher Scientific CEO Marc Casper in an interview Thursday with a UBS analyst said that in Q3 2026 pharmaceutical and biotechnology customers generated high-single-digit growth for the company, with that market expected to continue to strengthen.
“What we would expect is a strong year in pharma services with good growth, and the trends of like reshoring, this business benefits from that,” Casper said. “We won a lot of contracts to produce medicines in the United States to help our customers meet the obligations they have to the U.S. government. So, we have a unique position, and we feel good about the performance there.”
Newmark said there has been a resurgence in domestic drug manufacturing which has pushed employment in the sector to a 35-year high — an increase of 1.9% from a year ago. By comparison, the report noted total U.S. manufacturing employment has “declined significantly” for more than a year, with the potential for growth in domestic manufacturing operations providing “some upside” to the life science outlook.
However, DPR Construction’s report cautioned that market conditions across the industry vary by company and therapeutic portfolio.
“Organizations experiencing strong demand-driven revenue growth continue to aggressively expand their manufacturing footprint, to alleviate supply constraints and prepare for future product demand,” the report states. “In contrast, companies still facing post-pandemic declines, or generic revenue erosion, are tightening capital discipline to align with near-term profit forecasts.”
CDMOs poised for growth
Contract development and manufacturing organizations (CDMOs) attending the CPHI Milan conference in Italy last month reported that commercial manufacturing demand remains strong across drug substance and finished dose, according to William Blair analysts who cover the pharmaceutical outsourcing and services sector.
After meeting with more than 30 companies at the CPHI conference, the analysts in a note to investors said they are feeling more optimistic about the outlook for the outsourced pharma services industry based on demand that is supported by a broad range of products.
“Our conversations with CDMOs generally pointed to robust commercial demand across drug substance as well as finished dose manufacturing, especially for traditional biologics, with several companies also noting peptides and antibody-drug conjugates (ADCs) remain particularly attractive areas, while oligonucleotide production is emerging as another area of high demand,” the analysts wrote.
Staffing and recruiting firm Vector Talent’s CDMO Outlook for 2027 sees oligonucleotides “breaking out of rare disease” and predicts capacity “sells out before it’s built” with oligo Chemistry, Manufacturing, and Controls (CMC) talent becoming the “scarcest skill set in small-molecule adjacent manufacturing.”
About the Author
Greg Slabodkin
Editor in Chief
As Editor in Chief, Greg oversees all aspects of planning, managing, and producing the content for Pharma Manufacturing’s website and digital products, as well as the daily operations of its editorial team.
For more than 20 years, Greg has covered the healthcare, life sciences, and medical device industries for several trade publications. He is the recipient of a Post-Newsweek Business Information Editorial Excellence Award for his news reporting and a Gold Award for Best Case Study from the American Society of Healthcare Publication Editors. In addition, Greg is a Healthcare Fellow from the Society for Advancing Business Editing and Writing.
When not covering the pharma manufacturing industry, he is an avid Buffalo Bills football and Buffalo Sabres hockey fan, likes to kayak, and plays guitar.


